FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2295354328> ?p ?o ?g. }

• W2295354328 endingPage "463" @default.
• W2295354328 startingPage "452" @default.
• W2295354328 abstract "ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably develops, often with progression in the brain. Ceritinib is a more potent ALK inhibitor than crizotinib in vitro, crosses the blood-brain barrier in vivo, and shows clinical responses in patients with crizotinib-resistant disease. We aimed to assess whole-body activity of ceritinib in both ALK inhibitor-pretreated and ALK inhibitor-naive patients with ALK-rearranged NSCLC.ASCEND-1 was an open-label, phase 1 trial that recruited patients from 20 academic hospitals or cancer centres in 11 countries in Europe, North America, and Asia-Pacific. Eligible patients were aged 18 years or older with ALK-rearranged locally advanced or metastatic cancer that had progressed despite standard therapy (or for which no effective standard therapy existed), who had at least one measurable lesion at baseline. The primary objective (to determine the maximum tolerated dose) has been reported previously. This updated analysis includes all patients with ALK-rearranged NSCLC given oral ceritinib at the recommended dose of 750 mg/day in the dose-escalation and expansion phases. Here we report the secondary outcomes of overall response, duration of response, and progression-free survival, analysed in all patients who received at least one 750 mg dose of ceritinib. Exploratory analyses included retrospective analysis of intracranial activity by independent neuroradiologists, in patients with untreated or locally treated neurologically stable brain metastases at baseline. Safety was assessed in all patients who received at least one dose of ceritinib. This study is no longer recruiting patients; however, treatment and follow-up are ongoing. This study is registered with ClinicalTrials.gov, number NCT01283516.Between Jan 24, 2011, and July 31, 2013, 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC. At data cutoff (April 14, 2014), median follow-up was 11·1 months (IQR 6·7-15·2) and 147 (60%) patients had discontinued treatment, 98 (40%) as a result of disease progression. An overall response was reported in 60 (72% [95% CI 61-82]) of 83 ALK inhibitor-naive patients and 92 (56% [49-64]) of 163 ALK inhibitor-pretreated patients. Median duration of response was 17·0 months (95% CI 11·3-non-estimable [NE]) in ALK inhibitor-naive patients and 8·3 months (6·8-9·7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18·4 months (95% CI 11·1-NE) in ALK inhibitor-naive patients and 6·9 months (5·6-8·7) in ALK inhibitor-pretreated patients. Of 94 patients with retrospectively confirmed brain metastases and at least one post-baseline MRI or CT tumour assessment, intracranial disease control was reported in 15 (79% [95% CI 54-94]) of 19 ALK inhibitor-naive patients and in 49 (65% [54-76]) of 75 ALK inhibitor-pretreated patients. Of these 94 patients, 11 had measurable brain lesions and no previous radiotherapy to the brain, six of whom achieved a partial intracranial response. Serious adverse events were recorded in 117 (48%) of 246 patients. The most common grade 3-4 laboratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]). The most common grade 3-4 non-laboratory adverse events were diarrhoea and nausea, both of which occurred in 15 (6%) patients. Two on-treatment deaths during the study were deemed to be related to study drug by the investigators, one due to interstitial lung disease and one as a result of multiorgan failure that occurred in the context of infection and ischaemic hepatitis.The durable whole-body responses reported, together with the intracranial activity, support a clinical benefit for treatment with ceritinib in patients with ALK-rearranged NSCLC who have received crizotinib, or as an alternative to crizotinib. A confirmatory phase 2 clinical trial is ongoing to assess ceritinib activity in patients with ALK-rearranged NSCLC and brain or leptomeningeal metastases.Novartis Pharmaceuticals Corporation." @default.
• W2295354328 created "2016-06-24" @default.
• W2295354328 creator A5004871362 @default.
• W2295354328 creator A5013804417 @default.
• W2295354328 creator A5016978421 @default.
• W2295354328 creator A5021409571 @default.
• W2295354328 creator A5021704329 @default.
• W2295354328 creator A5023531951 @default.
• W2295354328 creator A5025511599 @default.
• W2295354328 creator A5029761367 @default.
• W2295354328 creator A5031801246 @default.
• W2295354328 creator A5036507802 @default.
• W2295354328 creator A5044353569 @default.
• W2295354328 creator A5045959942 @default.
• W2295354328 creator A5060033755 @default.
• W2295354328 creator A5061012285 @default.
• W2295354328 creator A5062234802 @default.
• W2295354328 creator A5063823247 @default.
• W2295354328 creator A5070256948 @default.
• W2295354328 creator A5073397759 @default.
• W2295354328 creator A5080311196 @default.
• W2295354328 creator A5082045927 @default.
• W2295354328 creator A5082517668 @default.
• W2295354328 date "2016-04-01" @default.
• W2295354328 modified "2023-10-17" @default.
• W2295354328 title "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial" @default.
• W2295354328 cites W1974903221 @default.
• W2295354328 cites W1981743826 @default.
• W2295354328 cites W1989544027 @default.
• W2295354328 cites W1990626198 @default.
• W2295354328 cites W1994389066 @default.
• W2295354328 cites W2002937040 @default.
• W2295354328 cites W2010619956 @default.
• W2295354328 cites W2030227571 @default.
• W2295354328 cites W2041835001 @default.
• W2295354328 cites W2043537675 @default.
• W2295354328 cites W2050249255 @default.
• W2295354328 cites W2065477010 @default.
• W2295354328 cites W2074782882 @default.
• W2295354328 cites W2077435197 @default.
• W2295354328 cites W2096156234 @default.
• W2295354328 cites W2099530756 @default.
• W2295354328 cites W2099725888 @default.
• W2295354328 cites W2104830962 @default.
• W2295354328 cites W2111724182 @default.
• W2295354328 cites W2113327188 @default.
• W2295354328 cites W2123394258 @default.
• W2295354328 cites W2134630203 @default.
• W2295354328 cites W2134787029 @default.
• W2295354328 cites W2147038864 @default.
• W2295354328 cites W2149152398 @default.
• W2295354328 cites W2151116840 @default.
• W2295354328 cites W2166138807 @default.
• W2295354328 cites W2224395257 @default.
• W2295354328 cites W2472128711 @default.
• W2295354328 cites W2480872124 @default.
• W2295354328 doi "https://doi.org/10.1016/s1470-2045(15)00614-2" @default.
• W2295354328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5063047" @default.
• W2295354328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26973324" @default.
• W2295354328 hasPublicationYear "2016" @default.
• W2295354328 type Work @default.
• W2295354328 sameAs 2295354328 @default.
• W2295354328 citedByCount "397" @default.
• W2295354328 countsByYear W22953543282016 @default.
• W2295354328 countsByYear W22953543282017 @default.
• W2295354328 countsByYear W22953543282018 @default.
• W2295354328 countsByYear W22953543282019 @default.
• W2295354328 countsByYear W22953543282020 @default.
• W2295354328 countsByYear W22953543282021 @default.
• W2295354328 countsByYear W22953543282022 @default.
• W2295354328 countsByYear W22953543282023 @default.
• W2295354328 crossrefType "journal-article" @default.
• W2295354328 hasAuthorship W2295354328A5004871362 @default.
• W2295354328 hasAuthorship W2295354328A5013804417 @default.
• W2295354328 hasAuthorship W2295354328A5016978421 @default.
• W2295354328 hasAuthorship W2295354328A5021409571 @default.
• W2295354328 hasAuthorship W2295354328A5021704329 @default.
• W2295354328 hasAuthorship W2295354328A5023531951 @default.
• W2295354328 hasAuthorship W2295354328A5025511599 @default.
• W2295354328 hasAuthorship W2295354328A5029761367 @default.
• W2295354328 hasAuthorship W2295354328A5031801246 @default.
• W2295354328 hasAuthorship W2295354328A5036507802 @default.
• W2295354328 hasAuthorship W2295354328A5044353569 @default.
• W2295354328 hasAuthorship W2295354328A5045959942 @default.
• W2295354328 hasAuthorship W2295354328A5060033755 @default.
• W2295354328 hasAuthorship W2295354328A5061012285 @default.
• W2295354328 hasAuthorship W2295354328A5062234802 @default.
• W2295354328 hasAuthorship W2295354328A5063823247 @default.
• W2295354328 hasAuthorship W2295354328A5070256948 @default.
• W2295354328 hasAuthorship W2295354328A5073397759 @default.
• W2295354328 hasAuthorship W2295354328A5080311196 @default.
• W2295354328 hasAuthorship W2295354328A5082045927 @default.
• W2295354328 hasAuthorship W2295354328A5082517668 @default.
• W2295354328 hasBestOaLocation W22953543282 @default.
• W2295354328 hasConcept C117643217 @default.
• W2295354328 hasConcept C121608353 @default.
• W2295354328 hasConcept C126322002 @default.
• W2295354328 hasConcept C143998085 @default.

• next